Cognition Therapeutics Valuation
| CGTX Stock | USD 0.45 0.02 4.65% |
Cognition Therapeutics is undervalued. Cognition Therapeutics shows a prevailing Real Value of $1.98 per share. The current price of the firm is $0.45. Our model approximates the value of Cognition Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 2.24 %, return on equity of -1.57, and Current Valuation of (5.18 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cognition Therapeutics' valuation include:
Undervalued
Today
Please note that Cognition Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Cognition Therapeutics is based on 3 months time horizon. Increasing Cognition Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cognition Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cognition Stock. However, Cognition Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.45 | Real 1.98 | Target 6.5 | Hype 0.44 | Naive 0.51 |
The intrinsic value of Cognition Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cognition Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cognition Therapeutics helps investors to forecast how Cognition stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cognition Therapeutics more accurately as focusing exclusively on Cognition Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cognition Therapeutics' intrinsic value based on its ongoing forecasts of Cognition Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cognition Therapeutics' closest peers.
Cognition Therapeutics Cash |
|
Cognition Valuation Trend
Analysing the historical paterns of Cognition Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Cognition Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Cognition Therapeutics Total Value Analysis
Cognition Therapeutics is currently anticipated to have valuation of (5.18 M) with market capitalization of 18.9 M, debt of 535 K, and cash on hands of 46.61 M. The negative valuation of Cognition Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Cognition Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.18 M) | 18.9 M | 535 K | 46.61 M |
Cognition Therapeutics Asset Utilization
One of the ways to look at asset utilization of Cognition is to check how much profit was generated for every dollar of assets it reports. Cognition Therapeutics shows a negative utilization of assets of -1.03 percent, losing $0.0103 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cognition Therapeutics shows how discouraging it operates for each dollar spent on its assets.Cognition Therapeutics Ownership Allocation
Cognition Therapeutics holds a total of 41.55 Million outstanding shares. Almost 79.87 percent of Cognition Therapeutics outstanding shares are held by general public with 2.24 (percent) owned by insiders and only 17.89 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cognition Therapeutics Profitability Analysis
Net Loss for the year was (33.97 M) with profit before overhead, payroll, taxes, and interest of 0.About Cognition Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Cognition Therapeutics. We calculate exposure to Cognition Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cognition Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -226.8 K | -238.1 K |
Cognition Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 39.7 M |
Cognition Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Cognition Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cognition we look at many different elements of the entity such as Cognition's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cognition Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cognition Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cognition Therapeutics' worth.Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.